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Background Patients with hypertension and cardiovascular disease (CVD), diabetes, or chronic kidney disease (CKD)
usually require two or more antihypertensive agents to achieve blood pressure (BP) goals.
Methods The efficacy/safety of olmesartan (OM) 40 mg, amlodipine besylate (AML) 10 mg, and hydrochlorothiazide
(HCTZ) 25 mg versus the component dual-combinations (OM 40/AML 10 mg, OM 40/HCTZ 25 mg, and AML
10/HCTZ 25 mg) was evaluated in participants with diabetes, CKD, or chronic CVD in the Triple Therapy with
Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in Hypertensive Patients Study (TRINITY). The primary
efficacy end point was least squares (LS) mean reduction from baseline in seated diastolic BP (SeDBP) at week 12.
Secondary end points included LS mean reduction in SeSBP and proportion of participants achieving BP goal
(<130/80 mm Hg) at week 12 (double-blind randomized period), and LS mean reduction in SeBP and BP goal
achievement at week 52/early termination (open-label period).
Results At week 12, OM 40/AML 10/HCTZ 25 mg resulted in significantly greater SeBP reductions in participants
with diabetes (−37.9/22.0 mm Hg vs −28.0/17.6 mm Hg for OM 40/AML 10 mg, −26.4/14.7 mm Hg for OM 40/HCTZ
25 mg, and −27.6/14.8 mm Hg for AML 10/HCTZ 25 mg), CKD (−44.3/25.5 mm Hg vs −39.5/23.8 mm Hg for OM
40/AML 10 mg, −25.3/17.0 mm Hg for OM 40/HCTZ 25 mg, and −33.4/20.6 mm Hg for AML 10/HCTZ 25 mg), and
chronic CVD (−37.8/20.6 mm Hg vs −31.7/18.2 mm Hg for OM 40/AML 10 mg, −30.9/17.1 mm Hg for OM 40/HCTZ
25 mg, and −27.5/16.1 mm Hg for AML 10/HCTZ 25 mg) (P<0.05 for all subgroups vs dual-component treatments).
BP goal achievement was greater for participants receiving triple-combination treatment compared with the
dual-combination treatments, and was achieved in 41.1%, 55.0%, and 38.9% of participants with diabetes, CKD, and
chronic CVD on OM 40/AML 10/HCTZ 25 mg, respectively. At week 52, there was sustained BP lowering with the
OM/AML/HCTZ regimen. Overall, the triple combination was well tolerated.
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Conclusions In patients with diabetes, CKD, or chronic CVD, short-term (12 weeks) and long-term treatment with
OM 40/AML 10/HCTZ 25 mg was well tolerated, lowered BP more effectively, and enabled more participants to
reach BP goal than the corresponding 2-component regimens.
Trial Identification Number: NCT00649389
Keywords: Hypertension, Diabetes mellitus, Chronic kidney disease, Cardiovascular diseases, Drug combinationsBackground
Hypertension is an important risk factor for develop-
ment of cardiovascular disease (CVD) and chronic kid-
ney disease (CKD) [1-3]. According to previous
estimates, the National Health and Nutrition Examin-
ation Survey (2005–2008) showed that 98 million (21%)
Americans have hypertension (defined as blood pressure
[BP] >140/90 mm Hg). According to new estimates, an
additional 52 million (11%) of American adults (for a
total of 150 million adults [32%]) have uncontrolled BP
requiring treatment (as defined by the American Heart
Association Task Force as BP >140/90 mm Hg for low-
risk individuals; >130/80 mm Hg for Framingham risk
score >10%, CKD, diabetes, and CVD; and >120/80 for
congestive heart failure). Adults with diabetes (50.6 mil-
lion), CKD (43.7 million), and CVD (43.3 million) have
the greatest prevalence of uncontrolled BP [4]. Hyper-
tension is present in nearly 75% of patients with CVD,
including coronary artery disease, stroke, diabetes, CKD,
and peripheral artery disease [5-7]; however, it is esti-
mated that only 53% of patients receiving antihypertensive
treatment achieve BP control [7]. By 2030, it is estimated
that 40.5% of the US population will have CVD [8].
The prevalence of hypertension is disproportionately high
in patients who have diabetes [9], and individuals who have
hypertension are nearly 2.5 times more likely to develop
diabetes within 6 years than those without hypertension.
Elevated BP is an important modifiable risk factor in
patients with CKD, and BP reduction has the potential to
both reduce cardiovascular death and attenuate progression
of kidney disease [10-12]. It is estimated that triple-
combination therapy is needed in at least 25% of all patients
with hypertension in order to control BP [13]. Individuals
who have hypertension and diabetes, CKD, or CVD are
likely to need multiple antihypertensive agents to achieve
the lower BP goals recommended in these high-risk popu-
lations [5,6]. Furthermore, single-pill combination therapy
may result in increased adherence through reduction in pill
burden and simplification of the therapeutic regimen [14].
A study including ~85,000 patients from Kaiser Perma-
nente found that adherence decreased when the number of
medications prescribed increased. In this study, antihyper-
tensive medication adherence levels were 77.2%, 69.7%,
62.9%, and 55.5% in patients who received 1-, 2-, 3-, or 4-
drug regimens, respectively [15].The triple combination of olmesartan medoxomil (OM)
40 mg, amlodipine besylate (AML) 10 mg, and hydrochlor-
othiazide (HCTZ) 25 mg resulted in statistically signifi-
cantly greater reductions in seated diastolic BP (SeDBP)
and seated systolic BP (SeSBP) than the component dual-
combination treatments in the Triple Therapy with Olme-
sartan Medoxomil, Amlodipine, and Hydrochlorothiazide
in Hypertensive Patients Study (TRINITY) [16]. During the
40-week open-label extension period of the TRINITY study,
continued administration of OM/AML/HCTZ triple-
combination regimens demonstrated maintenance of the
BP-lowering effects observed in the double-blind period of
the study [17]. Furthermore, in the Blood Pressure Control
in All Subgroups with Hypertension (BP-CRUSH) study
(N=999), the addition of HCTZ to a single-pill combination
of AML/OM allowed more patients to achieve SeBP goals
[18].
The objective of these subgroup analyses was to compare
the triple-combination treatment of OM 40/AML 10/HCTZ
25 mg with the component dual-combination treatments
(OM 40/AML 10 mg, OM 40/HCTZ 25 mg, and AML 10/
HCTZ 25 mg) in participants from the TRINITY study who
had hypertension and diabetes (prespecified analysis) [19],
CKD (prespecified analysis), or chronic CVD (post hoc ana-
lysis), and to evaluate the long-term efficacy and safety of
OM/AML/HCTZ in these high-risk subgroups.
Methods
Study population
Individuals in the TRINITY study (NCT00649389; http://
clinicaltrials.gov/ct2/show/NCT00649389) were aged ≥18
years with a mean SeBP ≥140/100 or ≥160/90 mm Hg (off
antihypertensive medication) [16]. Persons with type 1 or
type 2 diabetes controlled on a stable regimen with diet, in-
sulin, or oral antidiabetes medications for ≥30 days and
persons with CKD (creatinine clearance ≥30 mL/min and
≤60 mL/min) were eligible for inclusion. Persons with left
ventricular hypertrophy, stable angina, peripheral vascular
disease, and hypertensive retinopathy were also eligible for
inclusion. Exclusion criteria included uncontrolled diabetes
(with or without treatment) (ie, HbA1c >9.0%), stage IV
CKD (ie, estimated glomerular filtration rate <30 mL/min/
1.73 m2), history of a recent stroke or transient ischemic
attack, myocardial infarction, percutaneous coronary inter-
vention, coronary artery bypass surgery, and/or unstable
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Association class III or IV congestive heart failure. Persons
with secondary hypertension, symptomatic resting brady-
cardia, heart block greater than first-degree atrioventricular
block, and chronic atrial fibrillation or flutter were also
excluded. The study was conducted in accordance with the
institutional review board committee regulations and the
Declaration of Helsinki [20]. All patients provided written
informed consent at screening, before undergoing any
study procedures.
Study design
TRINITY was a phase 3, randomized, parallel-group study
conducted at 317 clinical sites in the United States and
Puerto Rico and consisted of a 12-week double-blind treat-
ment period followed by a 40-week open-label treatment
period. Details of the 12-week study design have been pub-
lished previously [16]; the study design for the 12-week
double-blind and open-label treatment periods is summar-
ized in Figure 1. Eligible study participants (stratified by
age, race, and diabetes status) were randomized to a regi-
men that resulted in the 4 treatment groups that received4 keeW2 keeW0 keeWWeek -3 Week 12 Week 14 Week 16 Week 52
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Figure 1 TRINITY study design (randomized, double-blind treatment period and open-label extension period). *BP goal is defined as
<130/80 mg Hg for participants with diabetes, CKD, or chronic CVD. AML, amlodipine besylate; BP, blood pressure; CKD, chronic kidney disease;
CVD, cardiovascular disease; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil. Adapted with permission from Elsevier [16].treatment from weeks 4 to 12 (OM 40/AML 10 mg [single-
pill combination], OM 40/HCTZ 25 mg [single-pill com-
bination], AML 10/HCTZ 25 mg [not a single-pill combin-
ation; given separately], or OM 40/AML 10/HCTZ 25 mg
[single-pill OM/HCTZ combination plus AML]). Although
stratification for chronic CVD or CKD was not part of the
stratification algorithm, there was a balanced distribution of
participants within each of the treatment arms for both
comorbidities in the total cohort. All participants received
dual-combination treatment for 4 weeks, except for a sub-
set of 36 control study participants who received placebo
for 2 weeks and were subsequently switched to 1 of the 3
dual-combination treatments from week 2 to week 4. At
week 4, participants were randomly maintained on dual-
combination treatment to week 12 or given triple-combination
treatment with OM 40/AML 10/HCTZ 25 mg until week
12. Participants completing the 12-week study were then
enrolled in a 40-week open-label treatment period. All par-
ticipants were switched to OM 40/AML 5/HCTZ 12.5 mg
(administered as OM 40/AML 5 mg single-pill combin-
ation plus HCTZ 12.5 mg) at the start of the open-label ex-
tension period. Participants not achieving BP goal (<140/90
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CKD, or chronic CVD) after 2 weeks (week 14) were ran-
domly titrated to 1 of 2 treatments (OM 40/AML 10/
HCTZ 12.5 mg [administered as OM 40/AML 10 mg
single-pill combination plus HCTZ 12.5 mg] or OM 40/
AML 5/HCTZ 25 mg [administered as OM 40/AML 5 mg
single-pill combination plus HCTZ 25 mg]). Participants
not achieving BP goal 2 weeks after this titration (week 16)
were further titrated to OM 40/AML 10/HCTZ 25 mg
(administered as OM 40/AML 10 mg single-pill combin-
ation plus HCTZ 25 mg) [17].
Study outcomes
The primary efficacy end point of the subgroup analyses
was the least squares (LS) mean reduction from baseline
in SeDBP at week 12 (primary efficacy registration re-
quirement for OM/AML/HCTZ). Secondary end points
included LS mean reduction in SeSBP and proportion of
participants reaching BP goal (<130/80 mm Hg) at week
12. For the open-label extension period, efficacy endpoints
included mean SeBP and proportion of participants
achieving BP goal (<130/80 mm Hg) at weeks 12, 14, 16,
and 52/early termination (ET). Safety assessments included
adverse events (AEs), clinical laboratory tests, vital signs,
physical examinations, and 12-lead electrocardiograms.
Statistical analysis
The primary efficacy analysis population was defined as
all participants who received at least 1 dose of study
medication and had assessments for SeDBP at baseline
and at least once post dose. The safety population (for
AE assessment) included all participants receiving at
least 1 dose of study medication at or beyond the week 4
visit of the 12-week double-blind period.
For the double-blind treatment period, two-sided
P values for testing the significance of the triple-
combination treatment versus each dual-combination
treatment were derived from an analysis of covariance
(ANCOVA) model that had baseline BP as a covariate
and fixed effects of final randomized treatment, sub-
group (eg, diabetes status subgroup), and final rando-
mized treatment by subgroup interaction. For each
comparison, the LS mean difference, corresponding
standard error (SE), and two-sided P values were derived
from the model. The proportion of participants reach-
ing BP goal in each treatment group was summarized
and analyzed using the chi square test. Comparisons
between triple-combination treatment and each dual-
combination treatment were performed using Fisher’s
exact test at a 0.05 significance level. The last obser-
vation carried forward (LOCF) approach was used for
ET measurements during double-blind treatment.
Summary statistics by dosing regimen were used to




A total of 2492 participants were randomized into the
study, of whom 2116 completed the 12-week double-
blind treatment period, 2112 entered the 40-week open-
label extension period (4 participants completed the
double-blind period of the study, but did not continue in
the open-label period: 2 individuals withdrew consent
and 2 individuals discontinued from the study due to
AEs), and 1796 completed the study (Figure 2). Of the
randomized participants, 387 (15.5%) had diabetes, 103
(4.1%) had CKD, and 227 (9.1%) had chronic CVD. Par-
ticipants with comorbid diabetes, CKD, and/or CVD
were included in each applicable subgroup. Baseline
characteristics of these subgroups are summarized by
treatment arm in Table 1. For the diabetes, CKD, and
chronic CVD subgroups, mean age was 58.7, 70.1, and
59.6 years and baseline BP was 171.7/98.5, 173.3/96.6,
and 173.0/100.4 mm Hg, respectively.
Efficacy
Week 12
In study participants with diabetes, CKD, and chronic
CVD, triple-combination treatment with OM 40/AML
10/HCTZ 25 mg resulted in greater BP reductions and a
greater proportion of participants achieving BP goal of
<130/80 mm Hg at week 12 (LOCF) compared with the
dual-combination treatments (Figure 3A, 3B and 3C).
Mean SeBP at week 12 was 131.8/77.3, 127.0/72.9, and
132.3/79.9 mm Hg for participants with diabetes, CKD,
and chronic CVD, respectively. The proportion of par-
ticipants receiving triple-combination treatment who
reached BP goal in each of these subgroups was 41.1%
(diabetes), 55.0% (CKD), and 38.9% (chronic CVD).
Week 52
Mean BP and proportion of participants reaching BP
goal (<130/80 mm Hg) during the open-label extension
period in the diabetes, CKD, and chronic CVD sub-
groups is summarized in Table 2. In the diabetes, CKD,
and chronic CVD subgroups, mean SeBP at week 52/ET
ranged from 121.4–136.7/74.9–79.7, 118.4–134.0/70.9–
75.0, and 127.1–138.4/77.1–82.3 mm Hg, respectively.
BP goal was reached by an average of 44.3%, 51.7%, and
33.7% of participants with diabetes, CKD, and chronic
CVD, respectively.
Safety
No new safety concerns were identified for either the
triple- or dual-combination treatments that were not
known to occur with the individual component therapies.
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and chronic CVD subgroups during the double-blind
treatment period are summarized in Table 3. At week 12,
205 (56.3%), 56 (57.7%), and 119 (57.8%) study partici-
pants with diabetes, CKD, and chronic CVD, respectively,
had a TEAE. Across all treatment groups for each sub-
group, most TEAEs were considered mild or moderate in
severity. In total, 11 (3.0%), 3 (3.1%), and 6 (2.9%) partici-
pants with diabetes, CKD, and chronic CVD had a serious
AE (SAE) and 11 (3.0%), 3 (3.1%), and 6 (2.9%) discontin-
ued from the study due to a TEAE.
The safety profile for these 3 subgroups during the open-
label treatment period is summarized in Table 4. The most
common TEAEs (≥5%) across doses during the open-label
extension period were upper respiratory tract infection
(11; 5.4%) in participants with diabetes; dizziness (3; 9.4%),
nasopharyngitis (3; 7.7%), and urinary tract infection
(3; 7.7%) in participants with CKD; and dizziness (6; 6.3%)
and cough (5; 5.3%) in participants with chronic CVD.R
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Figure 2 Participant disposition. AML, amlodipine besylate; HCTZ, hydroAlthough small changes were observed in serum
chemistry and hematology parameters, there was no ap-
parent relationship to the dose or combination of ther-
apy, and none were considered clinically significant. For
the total cohort at week 12/ET, mean glucose levels
(non-fasted) were 113.6 mg/dL (baseline: 108.5 mg/dL)
for OM 40/AML 10/HCTZ 25 mg; 114.1 mg/dL (base-
line: 110.2 mg/dL) for OM 40/AML 10 mg; 113.3 mg/dL
(baseline: 109.9 mg/dL) for OM 40/HCTZ 25 mg; and
117.0 mg/dL (baseline: 107.7 mg/dL) for AML 10/HCTZ
25 mg. Mean creatinine at week 12/ET was 0.98 mg/dL
(baseline: 0.92 mg/dL) for OM 40/AML 10/HCTZ 25
mg; 0.92 mg/dL (baseline: 0.95 mg/dL) for OM 40/AML
10 mg; 1.0 mg/dL (baseline: 0.94 mg/dL) for OM 40/
HCTZ 25 mg; and 0.94 mg/dL (baseline: 0.93 mg/dL)
for AML 10/HCTZ 25 mg. Creatinine clearance was
112.5 mL/min (baseline: 119.5 mL/min); 121.8 mL/min
(baseline: 121.8 mL/min); 109.5 mL/min (baseline: 117.7
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chlorothiazide; OM, olmesartan medoxomil.
Table 1 Demographic and baseline characteristics of the diabetes, CKD, and chronic CVD subgroups (randomized set)


































OM 40/ AML 10/
HCTZ
25 mg
(n=100) (n=99) (n=92) (n=96) (n=29) (n=25) (n=29) (n=20) (n=56) (n=61) (n=55) (n=55)
Age, mean (SD), yrs 59.7 (8.9) 60.3 (8.7) 56.5 (9.4) 58.1 (9.4) 71.0 (7.8) 71.5 (9.4) 69.4 (9.5) 68.1 (10.0) 60.2 (11.2) 61.1 (9.8) 58.2 (11.0) 58.6 (10.9)
Male, n (%) 60 (60.0) 54 (54.5) 52 (56.5) 51 (53.1) 9 (31.0) 10 (40.0) 10 (34.5) 5 (25.0) 40 (71.4) 38 (62.3) 34 (61.8) 39 (70.9)
Ethnicity
Hispanic/Latino, n (%) 21 (21.0) 18 (18.2) 13 (14.1) 15 (15.6) 1 (3.4) 2 (8.0) 3 (10.3) 2 (10.0) 8 (14.3) 5 (8.2) 7 (12.7) 8 (14.5)
Race
White, n (%) 72 (72.0) 73 (73.7) 58 (63.0) 67 (69.8) 18 (62.1) 19 (76.0) 21 (72.4) 13 (65.0) 40 (71.4) 45 (73.8) 37 (67.3) 35 (63.6)
Black, n (%) 26 (26.0) 24 (24.2) 29 (31.5) 25 (26.0) 9 (31.0) 5 (20.0) 7 (24.1) 6 (30.0) 16 (28.6) 16 (26.2) 18 (32.7) 17 (30.9)
Obesity, n (%)* 77 (77.0) 74 (74.7) 71 (77.2) 73 (76.0) 9 (31.0) 2 (8.0) 7 (24.1) 6 (30.0) 32 (57.1) 40 (65.6) 35 (63.6) 33 (60.0)
Hypertension duration,
mean (SD), y
12.8 (9.6) 13.2 (10.5) 11.2 (9.6) 10.7 (9.8) 12.1 (8.0) 14.0 (10.0) 13.0 (9.3) 14.8 (14.4) 12.0 (8.0) 15.0 (12.3) 12.9 (9.9) 13.3 (11.0)









































Figure 3 (See legend on next page.)
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Figure 3 Diabetes (A), CKD (B), and chronic CVD (C) subgroups: LS Mean (SE) reductions in SeBP and proportion of participants reaching BP
goal (<130/80 mm Hg) at week 12 (LOCF). Specific P values are found beneath each panel. AML, amlodipine besylate; BP, blood pressure; CKD, chronic
kidney disease; CVD, cardiovascular disease; HCTZ, hydrochlorothiazide; LOCF, last observation carried forward; LS, least squares; OM, olmesartan
medoxomil; SE, standard error.
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rate, electrocardiograms, or physical examinations were
observed during the treatment period of the study.
Discussion
The current subgroup analyses demonstrated the effect-
iveness of triple-combination treatment in difficult-
to-treat participants with hypertension and diabetes, CKD,
or chronic CVD. BP reductions with triple-combination
treatment in these subgroups at week 12 were comparable
to those for the overall study cohort (−37/22 mm Hg)
[16]. Long-term treatment with varying doses of OM/
AML/HCTZ in these subgroups resulted in similar
BP-lowering effects for those receiving triple-combination
treatment during the double-blind period of the study.
Triple-combination treatment also enabled these high-risk
subgroups to achieve BP goal (<130/80 mm Hg) at week
12 and at week 52. Triple-combination treatment was well
tolerated in these subgroups, with a low percentage of par-
ticipants discontinuing treatment across treatment groups




OM 40/AML 5/HCTZ 12.5 mg* 138.9/81.2 (17.4/9.6)
% to goal 22
Week 52/ET
n 62
OM 40/AML 5/HCTZ 12.5 mg 121.4/74.9 (14.5/8.8)
% to goal 65
n 34
OM 40/AML 5/HCTZ 25 mg 129.5/77.2 (15.6/9.9)
% to goal 38
n 40
OM 40/AML 10/HCTZ 12.5 mg 128.8/77.0 (11.6/8.5)
% to goal 50
n 197
OM 40/AML 10/HCTZ 25 mg 136.7/79.7 (15.2/9.7)
% to goal 24
BP data are mean (SD), mm Hg.
*Week 12 data are from the end of the double-blind treatment period before all pa
the open-label extension period.
AML, amlodipine; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascu
medoxomil; SD, standard deviation.presence of diabetes, CKD, or chronic CVD did not
change the AE profile of the drugs used in this ana-
lysis from that observed in the total TRINITY study
cohort [16].
It has been estimated that at least 75% of patients with
hypertension require combination therapy to maintain
BP control [14], and large clinical trials have reported
that 23-54% of participants require 3 or more antihyper-
tensive agents [21-24]. Thus, there is a growing em-
phasis on the need for practical strategies to consistently
achieve and maintain BP goals with the use of multiple
antihypertensive agents in clinical practice [14].
Single-pill combination therapy may improve BP control
through regimen simplification, which may lead to an im-
provement in patient adherence, reduction in physician
visits, and attainment of BP goals [14,16,25-30]. Single-pill
combinations have the potential to increase adherence to
therapy compared with free-dose combinations [31,32],
particularly in patients with hypertension and cardiovas-
cular comorbidities. Such patients are at increased risk of
nonadherence due to the need for multiple medicationsgoal (<130/80 mm Hg) at weeks 12 and 52/ET
CKD Chronic CVD
93 191
135.0/76.5 (20.6/10.9) 137.7/81.4 (15.7/10.3)
40 25
29 56
118.4/70.9 (12.6/7.9) 127.1/77.1 (18.8/12.4)
79 54
13 29
126.5/72.4 (22.5/10.5) 134.2/78.0 (17.0/11.6)
54 35
14 20
122.3/70.9 (15.6/8.1) 132.9/77.6 (11.1/8.5)
43 20
36 86
134.0/75.0 (17.7/10.3) 138.4/82.3 (16.2/10.6)
31 27
rticipants were switched to OM 40/AML 5/HCTZ 12.5 mg at the beginning of
lar disease; ET, early termination; HCTZ, hydrochlorothiazide; OM, olmesartan
Table 3 Study participants with treatment-emergent adverse events at week 12
Diabetes CKD Chronic CVD

































OM 40/ AML 10/
HCTZ
25 mg
(n=96) (n=91) (n=85) (n=92) (n=29) (n=22) (n=28) (n=18) (n=53) (n=54) (n=50) (n=49)
All TEAEs* 47 (49.0) 49 (53.8) 51 (60.0) 58 (63.0) 16 (55.2) 11 (50.0) 20 (71.4) 9 (50.0) 23 (43.4) 32 (59.3) 30 (60.0) 34 (69.4)
Severe TEAEs 4 (4.2) 4 (4.4) 5 (5.9) 6 (6.5) 0 2 (9.1) 2 (7.1) 1 (5.6) 2 (3.8) 2 (3.7) 2 (4.0) 5 (10.2)
Drug-related TEAEs† 21 (21.9) 16 (17.6) 17 (20.0) 25 (27.2) 5 (17.2) 8 (36.4) 10 (35.7) 3 (16.7) 9 (17.0) 11 (20.4) 13 (26.0) 17 (34.7)
Discontinuations
TEAEs 2 (2.1) 2 (2.2) 2 (2.4) 5 (5.4) 0 1 (4.5) 2 (7.1) 0 0 3 (5.6) 0 3 (6.1)
Drug-related TEAEs† 1 (1.0) 0 0 5 (5.4) 0 0 1 (3.6) 0 0 0 0 2 (4.1)
TEAEs (>5% in any treatment group)‡
Dizziness 3 (3.1) 3 (3.3) 3 (3.5) 7 (7.6) 1 (3.4) 1 (4.5) 3 (10.7) 1 (5.6) 1 (1.9) 5 (9.3) 2 (4.0) 7 (14.3)
Headache 5 (5.2) 8 (8.8) 2 (2.4) 5 (5.4) 1 (3.4) 3 (13.6) 1 (3.6) 0 1 (1.9) 3 (5.6) 1 (2.0) 2 (4.1)
Urinary tract infection 3 (3.1) 3 (3.3) 3 (3.5) 6 (6.5) 0 0 0 3 (16.7) 0 0 1 (2.0) 2 (4.1)
Upper respiratory tract infection 2 (2.1) 2 (2.2) 2 (2.4) 2 (2.2) 3 (10.3) 0 1 (3.6) 2 (11.1) 0 0 1 (2.0) 0
Bronchitis 2 (2.1) 0 1 (1.2) 3 (3.3) 0 1 (4.5) 0 2 (11.1) 0 3 (5.6) 2 (4.0) 1 (2.0)
Edema, peripheral 9 (9.4) 1 (1.1) 4 (4.7) 9 (9.8) 1 (3.4) 1 (4.5) 5 (17.9) 1 (5.6) 3 (5.7) 1 (1.9) 4 (8.0) 4 (8.2)
Fatigue 5 (5.2) 10 (11.0) 6 (7.1) 2 (2.2) 0 1 (4.5) 2 (7.1) 0 2 (3.8) 5 (9.3) 1 (2.0) 3 (6.1)
Joint swelling 1 (1.0) 0 2 (2.4) 1 (1.1) 4 (13.8) 0 0 1 (5.6) 1 (1.9) 1 (1.9) 3 (6.0) 3 (6.1)
Muscle spasms 4 (4.2) 2 (2.2) 0 3 (3.3) 1 (3.4) 2 (9.1) 0 0 0 3 (5.6) 3 (6.0) 0
Nausea 0 3 (3.3) 2 (2.4) 4 (4.3) 1 (3.4) 0 2 (7.1) 0 0 2 (3.7) 0 4 (8.2)
Diarrhea 1 (1.0) 2 (2.2) 2 (2.4) 2 (2.2) 4 (13.8) 0 1 (3.6) 0 2 (3.8) 0 1 (2.0) 0
Constipation 0 0 0 5 (5.4) 0 1 (4.5) 1 (3.6) 0 1 (1.9) 0 0 2 (4.1)
Hypokalemia 0 0 2 (2.4) 1 (1.1) 0 0 4 (14.3) 0 0 2 (3.7) 3 (6.0) 0
*TEAEs were AEs that emerged during treatment (absent pre-treatment or worsened relative to pre-treatment). TEAEs are defined as having a start date on/after the first dose of double-blind study medication and up
to the first dose of open-label study medication for participants continuing into the open-label period; or, for early terminated participants, up to and including 14 days after the last dose date of double-blind study
medication. All TEAEs are counted under the treatment the participant received from week 4 to week 12.
†Drug-related was defined as definitely, probably, or possibly related to randomized study medication.
‡TEAEs presented occurred in >5% and at least 3 study participants in any treatment group.
















Table 4 Study participants with adverse events during the open-label treatment period by onset dosing regimen
Diabetes CKD Chronic CVD




































(n=334) (n=139) (n=143) (n=203) (n=93) (n=35) (n=32) (n=39) (n=191) (n=74) (n=70) (n=95)
All AEs* 135 (40.4) 40 (28.8) 48 (33.6) 120 (59.1) 43 (46.2) 13 (37.1) 15 (46.9) 23 (59.0) 88 (46.1) 25 (33.8) 20 (28.6) 54 (56.8)
Severe AEs 12 (3.6) 2 (1.4) 4 (2.8) 8 (3.9) 4 (4.3) 1 (2.9) 1 (3.1) 4 (10.3) 7 (3.7) 1 (1.4) 3 (4.3) 5 (5.3)
Drug-related AEs† 37 (11.1) 9 (6.5) 12 (8.4) 28 (13.8) 14 (15.1) 4 (11.4) 5 (15.6) 8 (20.5) 30 (15.7) 8 (10.8) 4 (5.7) 24 (25.3)
Discontinuations
AEs 5 (1.5) 2 (1.4) 1 (0.7) 9 (4.4) 8 (8.6) 1 (2.9) 2 (6.3) 3 (7.7) 9 (4.7) 1 (1.4) 0 6 (6.3)
AEs starting in open-
label extension period
5 (1.5) 2 (1.4) 1 (0.7) 8 (3.9) 7 (7.5) 1 (2.9) 2 (6.3) 3 (7.7) 9 (4.7) 1 (1.4) 0 6 (6.3)
Drug-related AEs† 3 (0.9) 2 (1.4) 1 (0.7) 3 (1.5) 6 (6.5) 0 2 (6.3) 2 (5.1) 6 (3.1) 0 0 3 (3.2)
AEs (>5% in any
treatment group)‡
Dizziness 10 (3.0) 4 (2.9) 3 (2.1) 10 (4.9) 6 (6.5) 0 3 (9.4) 2 (5.1) 7 (3.7) 0 2 (2.9) 6 (6.3)
Urinary tract infection 13 (3.9) 4 (2.9) 2 (1.4) 9 (4.4) 1 (1.1) 1 (2.9) 0 3 (7.7) 4 (2.1) 0 1 (1.4) 3 (3.2)
Upper respiratory tract
infection
8 (2.4) 0 6 (4.2) 11 (5.4) 5 (5.4) 0 2 (6.3) 2 (5.1) 3 (1.6) 1 (1.4) 3 (4.3) 3 (3.2)
Nasopharyngitis 2 (0.6) 3 (2.2) 2 (1.4) 8 (3.9) 2 (2.2) 1 (2.9) 1 (3.1) 3 (7.7) 6 (3.1) 1 (1.4) 0 3 (3.2)
Cough 6 (1.8) 4 (2.9) 3 (2.1) 4 (2.0) 1 (1.1) 1 (2.9) 2 (6.3) 2 (5.1) 0 1 (1.4) 2 (2.9) 5 (5.3)
*Adverse events starting before the open-label extension period and not resolved by week 12 were counted under the final dosing regimen.
†Drug-related was defined as definitely, probably, or possibly related to randomized study medication.
‡AEs presented occurred in >5% and at least 3 study participants in any treatment group. Although a participant may have had 2 or more AEs, the participant is counted only once within a category. The same
participant may appear in different categories.
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in addition to antihypertensive medications [33,34].
Combining antihypertensive agents from different classes
has been estimated to produce BP reductions approxi-
mately 5 times greater than doubling the dose of any single
agent [35]. A meta-analysis has shown that one drug at
standard dose compared with a combination of 3 drugs at
half the standard dose reduced the incidence of coronary
heart disease by about 24% and 45%, respectively, and
stroke by 33% and 60%, respectively, in individuals aged 60
to 69 years with SeBP of 150/90 mm Hg [36]. The com-
plementary mechanisms of action of an angiotensin
receptor blocker, calcium channel blocker, and diur-
etic result in each agent targeting a separate pathway
and provide coverage for multiple different pathways
contributing to hypertension [14,25,35]. Additionally,
in patients with evidence of renal disease or at greater
risk of developing renal disease, such as those with
diabetes mellitus, it is recommended to use renin-
angiotensin-aldosterone system blocker–based com-
bination therapy [37,38].
Guidelines recognize that multiple antihypertensive
agents are often required in patients with diabetes and
CKD [5]. In addition, the American Heart Association
recommends starting with ≥2 antihypertensive agents in
patients with coronary artery disease [6]. The Seventh Re-
port of the Joint National Committee on Prevention, De-
tection, Evaluation, and Treatment of High Blood Pressure
(JNC 7) recommends a lower BP goal (<130/80 mm Hg)
for patients with diabetes or CKD, as both are major
risk factors for CVD [5]. Similarly, the American Heart
Association/American College of Cardiology recommends
a BP goal of <130/80 mm Hg for patients at high risk for or
with demonstrated coronary artery disease [6]. The
American College of Cardiology Foundation/American
Heart Association/American Medical Association–
Physician Consortium for Performance Improvement
2011 Performance Measures for Adults with Coronary
Artery Disease and Hypertension report also states that
lower BP targets may be appropriate for some patients
with coronary artery disease [39].
Despite the evidence supporting the benefit of tar-
geted BP control in high-risk patient groups, some
investigators have raised questions regarding incre-
mental benefit with more aggressive BP goals [40-42].
The European Society of Hypertension guidelines note
that many recommendations on hypertension manage-
ment are based on post hoc analyses rather than pro-
spective randomized trial data, with the latter being a
preferable evidence base for BP target recommenda-
tions in different patient groups [43]. At present, it
appears reasonable to adhere to currently established
guideline targets and goals of <130/80 mm Hg in
these high-risk patient groups.Limitations to the current subgroup and post hoc ana-
lyses include that statistical analyses between the sub-
groups were not completed because of the unequal
participant numbers in the subgroups. In addition, the
TRINITY study only evaluated the highest doses of each
of the 3 agents in the dual- and triple-combination regi-
mens; therefore, it does not provide information on the
efficacy and safety of the lower dosing regimens. This
study also excluded individuals with illnesses such as
symptomatic heart failure and therefore it cannot be
determined whether the triple-combination treatment is
appropriate for this patient population; caution must be
exercised regarding generalizability of these data to the
overall population.
Conclusions
Treatment with OM 40/AML 10/HCTZ 25 mg resulted
in greater reductions in SeBP compared with each dual-
combination treatment in high-risk subgroups of partici-
pants (diabetes, CKD or chronic CVD) from the TRIN-
ITY study. Also, a greater proportion of participants in
each subgroup achieved BP goal (<130/80 mm Hg) with
the triple combination at week 12 compared with the
dual-combination treatments, which was maintained
during the open-label period of the study. Long-term
triple-combination therapy was well tolerated.
Abbreviations
AEs: Adverse events; AML: Amlodipine besylate; ANCOVA: Analysis of
covariance; BP: Blood pressure; CKD: Chronic kidney disease;
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